Liz Thompson, Executive VP and Head of Research and Development for Acadia, has been interviewed recently by Global Genes about “Rett syndrome, how Daybue has changed the treatment landscape for people with the condition, and the company’s advancing pipeline to treat it”.
The podcast interview includes some interesting discussion about ACP-2591 (NNZ-2591).
A First for Rett Syndrome with More in the Pipeline
https://globalgenes.org/raredaily/a-first-for-rett-syndrome-with-more-in-the-pipeline/
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$14.20 |
Change
0.890(6.69%) |
Mkt cap ! $1.761B | |||
| Open | High | Low | Value | Volume |
| $13.50 | $14.26 | $12.96 | $9.111M | 655.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2000 | $14.17 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.23 | 3278 | 1 |
View Market Depth
| Last trade - 16.15pm 27/06/2025 (20 minute delay) ? |
| NEU (ASX) Chart |